WO2012103240A3 - Agents de liaison à un récepteur - Google Patents

Agents de liaison à un récepteur Download PDF

Info

Publication number
WO2012103240A3
WO2012103240A3 PCT/US2012/022583 US2012022583W WO2012103240A3 WO 2012103240 A3 WO2012103240 A3 WO 2012103240A3 US 2012022583 W US2012022583 W US 2012022583W WO 2012103240 A3 WO2012103240 A3 WO 2012103240A3
Authority
WO
WIPO (PCT)
Prior art keywords
domains
agonists
antagonists
chimeric
receptor type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/022583
Other languages
English (en)
Other versions
WO2012103240A2 (fr
Inventor
Thomas M. Barnes
Jinzhao Hou
Bracken M. King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carisma Therapeutics Inc
Original Assignee
Eleven Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleven Biotherapeutics Inc filed Critical Eleven Biotherapeutics Inc
Publication of WO2012103240A2 publication Critical patent/WO2012103240A2/fr
Publication of WO2012103240A3 publication Critical patent/WO2012103240A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des régions de la cytokine n'intervenant pas naturellement et pouvant être utilisées, entre autres, pour moduler la sensibilité de la signalisation cellulaire, pour traiter des troubles et pour détecter et/ou lier à des récepteurs cellulaires, ainsi que d'autres agents. Des exemples de régions de la cytokine peuvent contenir des restes aminoacides provenant d'au moins deux régions de la cytokine apparentées, par exemple, des caractéristiques de liaison à un récepteur, des caractéristiques de surface, des brins bêta et des boucles provenant d'au moins deux régions de la cytokine apparentées.
PCT/US2012/022583 2011-01-25 2012-01-25 Agents de liaison à un récepteur Ceased WO2012103240A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201161436184P 2011-01-25 2011-01-25
US201161436178P 2011-01-25 2011-01-25
US61/436,184 2011-01-25
US61/436,178 2011-01-25
US201161493966P 2011-06-06 2011-06-06
US201161493967P 2011-06-06 2011-06-06
US61/493,966 2011-06-06
US61/493,967 2011-06-06
US201161513472P 2011-07-29 2011-07-29
US201161513521P 2011-07-29 2011-07-29
US61/513,472 2011-07-29
US61/513,521 2011-07-29

Publications (2)

Publication Number Publication Date
WO2012103240A2 WO2012103240A2 (fr) 2012-08-02
WO2012103240A3 true WO2012103240A3 (fr) 2012-10-26

Family

ID=46581384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022583 Ceased WO2012103240A2 (fr) 2011-01-25 2012-01-25 Agents de liaison à un récepteur

Country Status (1)

Country Link
WO (1) WO2012103240A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059764B2 (en) 2014-01-10 2018-08-28 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33) and methods of making and using

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
SG10201606218WA (en) * 2011-07-29 2016-09-29 Eleven Biotherapeutics Inc Purified Proteins
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
WO2015138844A1 (fr) 2014-03-13 2015-09-17 Eleven Biotherapeutics, Inc. Procédés pour la production de formulations de protéines cytokine chimériques stables dans des récipients du type à soufflage/remplissage/fermeture
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
EP4118114A1 (fr) 2020-03-13 2023-01-18 Genentech, Inc. Anticorps anti-interleukine-33 et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047921A1 (fr) * 1997-04-21 1998-10-29 Schering Corporation Cytokines de mammifere; reactifs et procedes connexes
US7700318B2 (en) * 2004-08-25 2010-04-20 Amprotein Corporation Chimeric polypeptide and use thereof
WO2010081091A2 (fr) * 2009-01-09 2010-07-15 Schepens Eye Research Institute Compositions thérapeutiques pour le traitement de troubles de la cornée
WO2012016203A1 (fr) * 2010-07-29 2012-02-02 Eleven Biotherapeutics, Inc. Agonistes et antagonistes du récepteur chimérique d'il-1 de type i

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6018012A (en) 1998-07-20 2000-01-25 Callaway Golf Company Two-component polyurethane top coat for golf balls
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
CA2695374A1 (fr) 2007-08-15 2009-02-19 Amunix, Inc. Compositions et procedes d'amelioration de la production de polypeptides recombines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047921A1 (fr) * 1997-04-21 1998-10-29 Schering Corporation Cytokines de mammifere; reactifs et procedes connexes
US7700318B2 (en) * 2004-08-25 2010-04-20 Amprotein Corporation Chimeric polypeptide and use thereof
WO2010081091A2 (fr) * 2009-01-09 2010-07-15 Schepens Eye Research Institute Compositions thérapeutiques pour le traitement de troubles de la cornée
WO2012016203A1 (fr) * 2010-07-29 2012-02-02 Eleven Biotherapeutics, Inc. Agonistes et antagonistes du récepteur chimérique d'il-1 de type i

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A WINGREN: "Fusion of a Signal Sequence to the Interleukin-1[beta] Gene Directs the Protein from Cytoplasmic Accumulation to Extracellular Release", CELLULAR IMMUNOLOGY, vol. 169, no. 2, 1 May 1996 (1996-05-01), pages 226 - 237, XP055014943, ISSN: 0008-8749, DOI: 10.1006/cimm.1996.0113 *
CHARLES A. DINARELLO: "Immunological and Inflammatory Functions of the Interleukin-1 Family", ANNUAL REVIEW OF IMMUNOLOGY, vol. 27, no. 1, 1 April 2009 (2009-04-01), pages 519 - 550, XP055014922, ISSN: 0732-0582, DOI: 10.1146/annurev.immunol.021908.132612 *
DATABASE UniProt [Online] 13 July 2010 (2010-07-13), anonymous: "IL1F5_HUMAN", XP002682422, retrieved from www.uniprot.org Database accession no. Q9UBH0 *
DATABASE UniProt [Online] 13 July 2010 (2010-07-13), anonymous: "IL1RA_HUMAN", XP002682423, retrieved from www.uniprot.org *
DATABASE UniProt [Online] 23 July 2010 (2010-07-23), anonymous: "IL1RA_MOUSE", XP002682424, retrieved from www.uniprot.org Database accession no. P25085 *
DEH-MING CHANG ET AL: "Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation", IMMUNOLOGY, vol. 112, no. 4, 1 August 2004 (2004-08-01), pages 643 - 650, XP055014940, ISSN: 0019-2805, DOI: 10.1111/j.1365-2567.2004.01910.x *
ERIC S. FURFINE ET AL: "EBI-005: An IL-1 Receptor Inhibitor Designed for the Treatment of Dry Eye Syndrome", 7 May 2012 (2012-05-07), pages 1 - 1, XP055036406, Retrieved from the Internet <URL:http://www.elevenbio.com/pdf/Eleven_poster_042312_lowres.pdf> [retrieved on 20120827] *
HAL M. HOFFMAN ET AL: "Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies", ARTHRITIS & RHEUMATISM, vol. 58, no. 8, 30 July 2008 (2008-07-30), pages 2443 - 2452, XP055014926, ISSN: 0004-3591, DOI: 10.1002/art.23687 *
HEIDARY ET AL: "Long-range Coupling Between Separate Docking Sites in Interleukin-1beta", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 353, no. 5, 11 November 2005 (2005-11-11), pages 1187 - 1198, XP005152798, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2005.08.072 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059764B2 (en) 2014-01-10 2018-08-28 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33) and methods of making and using

Also Published As

Publication number Publication date
WO2012103240A2 (fr) 2012-08-02

Similar Documents

Publication Publication Date Title
MX360097B (es) Agonistas y antagonistas del receptor tipo i de il-1 quimérico.
HK1225742A1 (zh) TGF-β受体II型变体及其用途
WO2013131010A3 (fr) Fonction du récepteur de chimiokine ccr8 dans des métastases de mélanome
MX2020012240A (es) Agentes de ligacion agonistas del receptor tnf.
HK1220214A1 (zh) Fc变体
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
HK1254820A1 (zh) 免疫检查点嵌合受体疗法
PH12016500642B1 (en) Selective substituted quinoline compounds
WO2014042433A3 (fr) Composés et compositions de modulation de l&#39;activité du récepteur adénosine a3
WO2014089169A3 (fr) Immunothérapie par des agents de liaison
MX2019014654A (es) Agonistas de fgfr1 y sus metodos de uso.
DK3409269T3 (da) Stabiliserede formuleringer, der indeholder anti-interleukin-6-receptor- (IL-6R) antistoffer
MX368455B (es) Compuestos de tetrahidropirazolopirimidina.
WO2009095489A3 (fr) Séquences d&#39;acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
WO2012140274A3 (fr) Composés
WO2014145252A3 (fr) Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
DK2563400T3 (da) Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion
EP2395835A4 (fr) Agonistes et antagonistes du récepteur s1p5, et leurs procédés d&#39;utilisation
WO2015007536A3 (fr) Fusokines impliquant des cytokines ayant des affinités de liaison à leurs récepteurs fortement réduites
GB201017345D0 (en) Receptor antagonists
WO2012103360A3 (fr) Compositions de wnt et procédés d&#39;utilisation de celles-ci
HK1208232A1 (en) Gip-glp-1 dual agonist compounds and methods
WO2011018586A3 (fr) Methode de determination de la liaison d&#39;un compose donne a un recepteur membranaire.
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2013024040A3 (fr) Inhibiteurs de trimérisation de la superfamille des tnf

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12706353

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12706353

Country of ref document: EP

Kind code of ref document: A2